A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer. - A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.

Aichi Cancer Center Hospital0 个研究点目标入组 25 人开始时间: 2016年1月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Active multiple malignancy (2) History of severe drug-induced hypersensitivity (3) Symptomatic brain metastasis (4) Active infection (5) Interstitial pneumonia or pulmonary fibrosis (6) Serious complications (renal failure, liver failure, severe cardiac disease, uncontrolled diabetes, uncontrolled hypertension, ileus) (7) massive pleural, abdominal, or pericardial effusion (8) Administration of phenytoin or flucytosine (9) Systemic administration of steroid (10) Thromboembolism (grade 3 or higher) within 6 months before enrollment (11) Any major surgery or open biopsy within 4 weeks before scheduled date of treatment (14) Bleeding diathesis or tendency (13) Active peptic ulcer (14) History of gastrointestinal perforation within 1 year before enrollment (15) Clinically significant mental disorder (16) Positive for HBs antigen (17) Women who are pregnant or patients who are unwilling to avoid pregnancy (18) grade 2 or higher peripheral neuropathy (19) previous treatment with oxaliplatin (20) Patients who are inappropriate for the study in the opinion of the investigator

发起方

Aichi Cancer Center Hospital